Global Oncology Market to 2023 – Robust Growth Driven by Rising Prevalence and Increased Uptake of Immune Checkpoint Inhibitors

“The Report Global Oncology Market to 2023 – Robust Growth Driven by Rising Prevalence and Increased Uptake of Immune Checkpoint Inhibitors provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. – MarketResearchReports.biz”

About Oncology Market

In 2012, there were 32.6 million people living with any type of cancer within five years of diagnosis. These are generally incurable once they progress to the stage where they are unresectable. Chemotherapy compounds are a mainstay treatment for cancers of all types, at various disease stages. In a typical course of therapy for cancer, multiple chemotherapy compounds are administered sequentially in combination regimens, as an adjunct to surgery and radiation therapy. Chemotherapy drugs are cytotoxic to dividing cells, meaning that they act on both healthy and malignant tissues and are fairly toxic. However, they exert more damage on malignant tissue than healthy tissue due to the rapid cell cycle of cancer cells. The key cancer indications of this report are breast, colorectal, lung, and prostate and hematological cancers.

A number of common etiologic factors have been strongly characterized as raising the risk of developing cancer, including age, chronic inflammation, gender, obesity, tobacco usage and heritable cancer syndromes. The risk of cancer increases greatly in patients over the age of 65. Populations in developed countries are projected to become increasingly aged and show rising obesity incidence, which will drive both cancer prevalence and revenue growth for its treatments.

There has been a shift towards developing targeted therapies, such as mAbs and cell therapies. Targeted therapies, by their nature, have less toxicity associated with their use and as a result can be administered to more cancer patients, who are commonly elderly and have co-morbidities, therefore increasing the overall survival of this group and the number of treatment cycles they may receive. The most commercially successful oncology treatments are mAbs such as MabThera/Rituxan, Avastin and Herceptin.

Scope

Global revenue for the oncology market is forecast to grow at a Compound Annual Growth Rate (CAGR) of 10.66%, from $118.6 billion in 2016 to $241.0 billion in 2023. Which drugs will achieve blockbuster status and how will the key player companies perform during the forecast period?

The oncology pipeline is large and fairly diverse and contains 7,773 products. How does the composition of the pipeline compare with that of the existing market? What are the most popular types of molecule type and molecular target in the pipeline?

What mechanisms of action and molecule types are most common for pipeline products being trialed in the various key indications?

How will the market shares and CAGRs of the top 20 pharma companies compare within oncology?

What proportion of the key players’ revenues will be attributable to oncology products?

Reasons to buy

Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis

Visualize the composition of the oncology market across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players

Analyze the oncology pipeline and stratify by stage of development, molecule type and molecular target, with a granular breakdown across key indications

Understand the growth in patient epidemiology and market revenue for the oncology market globally and across the key players and product types

Stratify the market in terms of the generic and premium product revenue split between oncology products and assess the role of these product types in the treatment of the various cancers

Identify commercial opportunities in the oncology deals landscape by analyzing trends in licensing and co-development deals

VIEW SAMPLE PDF

Purchase this Market Research Report

Single License

$ 4995

Multiple License

$ 9990

Secure Payments

DOWNLOAD REPORT PDF

SAVE PAGE

SEND AN ENQUIRY

CHECK DISCOUNT

REQUEST QUOTE

ENQUIRY BEFORE BUY

Popular Reports

Get Sample copy of this Report @ https://www.marketresearchreports.biz/sample/sample/1245341

United States Tumor Necrosis Factor Market Report 2017

In this report, the United States Tumor Necrosis Factor market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.Geographically, this report splits the United States market into seven regions: The West

United States Peripheral Embolic Protection Device Market Report 2017

In this report, the United States Peripheral Embolic Protection Device market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.Geographically, this report splits the United States market into seven regions:

United States Pentoxifylline Drug Market Report 2017

In this report, the United States Pentoxifylline Drug market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.Geographically, this report splits the United States market into seven regions: The West S

United States Pentoxifylline Market Report 2017

In this report, the United States Pentoxifylline market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.Geographically, this report splits the United States market into seven regions: The West Southw

United States Opioid Antagonist Drug Market Report 2017

In this report, the United States Opioid Antagonist Drug market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.Geographically, this report splits the United States market into seven regions: The West

Table of Contents

1 Table of Contents 5

1.1 List of Tables 7

1.2 List of Figures 7

2 Introduction 10

2.1 Therapy Area Introduction 10

2.2 Symptoms 11

2.3 Diagnosis 12

2.4 Etiology and Pathophysiology 13

2.4.1 Etiology 13

2.4.2 Pathophysiology 15

2.5 Co-morbidities and Complications 16

2.6 Epidemiology Patterns – Prevalence, Patient Segmentation, and Diagnostic and Treatment Usage Rates 17

2.6.1 Breast Cancer 17

2.6.2 Colorectal Cancer 18

2.6.3 Lung Cancer 19

2.6.4 Prostate Cancer 20

2.6.5 Hematological Cancers 21

2.7 Prognosis 22

2.7.1 Breast Cancer 22

2.7.2 Colorectal Cancer 23

2.7.3 Non-Small-Cell Lung Cancer 23

2.7.4 Prostate Cancer 24

2.8 Treatment 25

2.8.1 Surgery and Radiation Therapy 25

2.8.2 Chemotherapy 26

2.8.3 Hormonal Therapies 28

2.8.4 Targeted Therapies 29

3 Key Marketed Products 31

3.1 Overview 31

3.2 MabThera/Rituxan (rituximab) 32

3.3 Avastin (bevacizumab) 33

3.4 Herceptin (trastuzumab) 35

3.5 Revlimid (lenalidomide) 37

3.6 Opdivo (nivolumab) 39

3.7 Xtandi (enzalutamide) 41

3.8 Gleevec/Glivec (imatinib mesylate) 42

3.9 Alimta (pemetrexed) 44

3.10 Zytiga (abiraterone acetate) 46

3.11 Conclusion 47

View Sample PDF @ https://www.marketresearchreports.biz/reports/1245341/global-oncology-to-robust-market-research-reports.pdf

4 Pipeline Landscape Assessment 49

4.1 Overview 49

4.2 Pipeline Development Landscape 50

4.3 Molecular Targets in the Pipeline 54

4.4 Clinical Trials 58

4.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target 58

4.4.2 Clinical Trial Size and Duration by Stage of Development, Indication, Molecule Type and Molecular Target 62

4.4.3 Clinical Trial Size and Duration by Stage of Development, Indication, Molecule Type and Molecular Target 66

4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target 70

4.4.5 Conclusion 74

4.5 Assessment of Key Pipeline Products 74

4.5.1 Durvalumab – AstraZeneca 74

4.5.2 Durvalumab and Tremelimumab – AstraZeneca 75

4.5.3 Abemaciclib – Eli Lilly 76

4.5.4 Rova-T (rovalpituzumab tesirine) – AbbVie 77

4.5.5 Neratinib – Puma Biotechnology 79

4.5.6 Acalabrutinib – AstraZeneca 80

4.5.7 KTE-C19 (Axicabtagene Ciloleucel) – Kite Pharma 81

4.5.8 Tisagenlecleucel-T – Novartis 83

4.5.9 Conclusion 84

5 Multi-scenario Market Forecast to 2023 85

5.1 Overall Market Size 85

5.2 Generic Penetration 101

5.3 Revenue Forecast by Molecular Target 103

5.3.1 Programmed Cell Death Protein 1/Programmed Cell Death 1 Ligand 1 103

5.3.2 Tumor Necrosis Factor 105

5.3.3 Tyrosine-Protein Kinase BTK 106

5.3.4 Cyclin-Dependent Kinases 107

5.3.5 Androgen Receptor 108

5.3.6 Vascular Endothelial Growth Factor 109

Send An Enquiry Request @ https://www.marketresearchreports.biz/sample/enquiry/1245341

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074

Website: http://www.marketresearchreports.biz/

E: sales@marketresearchreports.biz

Designed by CyFocus.com
Powered by CyFocus.net